ARTICLE IN PRESS



**Q3** 

**Q1**  SURGERY FOR OBESITY AND RELATED DISEASES

Surgery for Obesity and Related Diseases I (2015) 00–00

Original article

# Long-term outcomes of laparoscopic sleeve gastrectomy: a Lebanese center experience

Hanaa Dakour Aridi, M.D., Ramzi Alami, M.D., F.A.C.S., Hani Tamim, Ph.D., Ghassan Shamseddine, M.D., Tarek Fouani, M.P.H., Bassem Safadi, M.D., F.A.C.S.\*

Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon Received October 1, 2015; accepted November 23, 2015

### Abstract Q4 Background:

**Objectives:** The aim of this study was to assess the efficacy and safety of laparoscopic sleeve **Q5** gastrectomy (LSG) at 5 years and beyond.

Setting: Tertiary referral hospital between April 2007 and March 2015.

**Q6 Methods:** A retrospective review of 76 patients who underwent LSG at the authors' institution between April 2007 and March 2010.

**Results:** Mean preoperative body mass index (BMI) was  $42.8 \pm 7.1 \text{ kg/m}^2$ . Follow-up rates were 90.4%, 86.3%, and 77.8% at 5, 6, and 7 years, respectively. Percentage of excess weight loss (% EWL) was  $69.8\% \pm 28.7\%$  at 5 years,  $70.6\% \pm 32.7\%$  at 6 years, and  $76.6\% \pm 21.2\%$  at 7 years, respectively. Mean total weight loss was  $26.5\% \pm 8.7\%$ ,  $24.9\% \pm 8.8\%$ , and  $26.6\% \pm 6.0\%$  at 5, 6, and 7 years, respectively. %EWL at 5-years was significantly higher for patients with a preoperative BMI <45 kg/m<sup>2</sup> (83.1% versus 46.3%, P < .0001). LSG improved or resolved diabetes, hypertension, and asthma in 87.5%, 68%, and 81.7% of patients. Long-term complications included hiatal hernias necessitating repair (1.4%), incisional hernias (2.7%), and symptomatic gallstones (9.6%), as well as depression necessitating admission (4.1%). **Conclusion:** In the present patient population, LSG resulted in satisfactory %EWL and comorbidity resolution after 5 years. The results were excellent for patients with a BMI <45 kg/m<sup>2</sup>. De novo acid reflux symptoms developed in 1 of 5 patients. Choleithiasis necessitating cholecystectomy was the most common long-term complication. (Surg Obes Relat Dis 2015; 100-00.) (C) 2015 American Society for Metabolic and Bariatric Surgery. All rights reserved.

Keywords: Obesity; Weight loss; Bariatric surgery; Laparoscopic sleeve gastrectomy

The prevalence of obesity is increasing worldwide. According to the World Health Organization, >1.9 billion adults aged 18 years and older were overweight with a body mass index (BMI)  $\geq$  25 kg/m<sup>2</sup> in 2014. Of these, > 600 million were obese (BMI  $\geq$  30 kg/m<sup>2</sup>) [1]. Laparoscopic

http://dx.doi.org/10.1016/j.soard.2015.11.025

sleeve gastrectomy (LSG) is an increasingly popular bariatric intervention for the treatment of morbid obesity and its associated co-morbidities, including type 2 diabetes (T2D), hypertension, dyslipidemia, premature joint disease, sleep apnea, polycystic ovary syndrome, and nonalcoholic fatty liver disease [2]. Many studies have shown that LSG can be a single, safe, and effective treatment for patients with morbid obesity due to satisfactory weight loss results and co-morbidity resolution on short- and mid-term follow-up [3–8]. However, data on the long-term efficacy of this

<sup>&</sup>lt;sup>\*</sup>Correspondence: Bassem Y. Safadi, M.D., F.A.C.S., American University of Beirut Medical Center, PO Box: 11-0236, Riad El Solh, Beirut 1107 2020, Beirut, Lebanon.

E-mail: bs21@aub.edu.lb

<sup>54 1550-7289/© 2015</sup> American Society for Metabolic and Bariatric Surgery. All rights reserved.

2

70 procedure are still scarce [2,6], especially in the Middle East. A recent study from Kuwait with an average post-71 operative follow-up time of 3.3 years (range, 1-5 yr) found 72 a mean percentage excess weight loss (%EWL) of 73  $55.7\% \pm 23.0\%$  and resolution of nonalcoholic fatty liver 74 75 disease in more than half of the obese patient [9]. This study aims to assess the efficacy and safety of LSG at 76 5 years and beyond. This study was approved by the 77 78 Institutional Review Board at the American University of Beirut. For this type of study, formal consent is not 79 80 Q7 required.

## 82 Materials and methods

#### Patients

81

83

84

95

96

85 After receiving institutional review board approval, a 86 prospectively collected database of 76 patients who under-87 went LSG at the American University of Beirut Medical 88 Center and affiliate hospitals was retrospectively reviewed 89 by the senior author (B.Y.S.) between April 2007 and 90 March 2010. Patients were followed up by clinic visit and, 91 when not available, by telephone contact or e-mail until 92 March 2015 (providing, at least, a 5-year follow-up and, at 93 most, a 7-year follow-up). 94

# Data

97 Data collected included patients' demographic character-98 istics, anthropomorphic information (weight, height, and BMI), presence of medical co-morbidities, and postoper-99 ative complications. Weight loss was expressed as change 100 in BMI, percentage of total weight loss (%TWL), and % 101 EWL. Presence of T2D was defined as a glycosylated 102 hemoglobin (HbA1C) level  $\geq 6.5\%$  or fasting blood gluco-103 mg/dL. 104 se  $\geq 126$ Remission was defined as an HbA1C <6% or fasting blood glucose (FBG) <100 mg/ 105 dL in the absence of antidiabetic medications, and partial 106 remission was defined as an HbA1C 6-6.4% or FBG 100-107 125 mg/dL in the absence of antidiabetic medication. 108Improvement was defined as a statistically significant 109 110 reduction in HbA1C and FBG that did not meet the criteria for remission or as a decrease in antidiabetic medications 111 requirement (discontinuing insulin or 1 oral agent or 1/2 112 reduction in dose). Presence of hypertension included both 113 stage 1 (blood pressure: 120-159/90-99 mm Hg) and Stage 114 115 2 (> 160 / > 100). Improvement was defined as a decrease in dosage or number of antihypertensive medication; partial 116 remission as prehypertension values (120-140/80-89) when 117 off medication and complete remission as normal blood 118 pressure (<120/80) when off antihypertensive medication 119 120 as reported by the patient. Because many follow-ups were done via phone calls or e-mails, values were based solely on 121 patients' self-reports. Initial diagnosis of dyslipidemia was 122 123 based on high levels of low-density lipoprotein (>130 mg/dL), total cholesterol (>200mg/dL), or triglycerides (>150 mg/dL) 124

on initial assessment. Because laboratory testing of lipid 125 profile was lacking on most follow-ups, dyslipidemia outcomes are not reported. 127

For gastroesophageal reflux disease (GERD), improvement was subjective and based on improvement in symptoms severity or frequency or on decreased medication use. 130 Complete resolution meant absence of symptoms and no medication use. Similarly, for asthma and depression, remission and improvement were based on symptoms and medication use. 134

135

136

137

157

158

159

160

161

162

163

#### Surgical procedure

The procedure was performed under general anesthesia in 138 the supine position. The number of laparoscopic ports 139 ranged from 3 to 5 with a Nathanson liver blade to retract 140 the left lateral segment of the liver. The vessels along the 141 greater curvature were sealed and divided with the LigaSure 142 Atlas (Covidien, Boulder, CO) all the way to the angle of 143 His and to 3-5 cm proximal to the pylorus. All the 144 retrogastric adhesions were released so that the stomach 145 was quite floppy. A 36 French orogastric tube was placed 146 and oriented toward the antrum, and starting at approx-147 imately 4 cm proximal to the pylorus, the stomach was 148 stapled and divided along the 36 French orogastric tube 149 with an endoscopic stapler. The staple line was then sutured 150 with 2-0 PDS sutures serosa to serosa, and then the Q451 orogastric tube was removed. The ports were removed 152 under direct vision, and the stomach was retrieved through 153 the umbilical incision. The fascia at the umbilicus was 154 closed with PDS, and the skin was closed with absorbable 155 sutures. 156

#### Measure

%EWL was calculated using the formula:

$$\frac{100\% \times (initial_{weight} - Follow - up_{weight})}{(Initial_{weight} - IBW)}.$$

where ideal weight (IW) was considered as the weight 164 needed to achieve a BMI of 25 kg/m<sup>2</sup> [10]. Analysis was 165 conducted using SPSS (Statistical Package for Social 166 Sciences), version 22. Comparison of means from contin-167 uous variables was performed using paired 2-tailed Stu-168 dent's t test whereas comparison of co-morbidities at 169 baseline and after LSG used McNemar's test. Results were 170 represented as mean ± standard deviation and 95% con-171 fidence interval. Moreover, multivariate linear regression 172 analyses were carried out to identify the variables associated 173 with %EWL at 5 years, whereby factors found to be 174 significant at the univariate level or those of clinical 175 significance were included. The level of statistical signifi-176 cance was set at a P value <.05. Reinhold criteria were 177 used to assess if weight loss results were satisfactory. This 178 criteria distinguishes between excellent, good, fair, and poor 179

Download English Version:

# https://daneshyari.com/en/article/5661603

Download Persian Version:

https://daneshyari.com/article/5661603

Daneshyari.com